{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T23:40:47Z","timestamp":1790293247224,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,10]]},"DOI":"10.7759\/cureus.101212","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T09:06:07Z","timestamp":1768035967000},"source":"Crossref","is-referenced-by-count":4,"title":["The Impact of Glucagon-Like Peptide-1 (GLP-1) Agonists on Acne, Hidradenitis, and Sebaceous Activity"],"prefix":"10.7759","author":[{"given":"Azra","family":"Jabin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahab","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hammad","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zain Ullah","family":"Durrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khizer","family":"Hamza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiza","family":"Gul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sana","family":"Atta Ullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad","family":"Dayam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Yaseen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saleem","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1177\/10742484221146371","article-title":"Glucagon-like peptide-1 receptor agonists and dual glucose-dependent insulinotropic polypeptide\/glucagon-like peptide-1 receptor agonists in the treatment of obesity\/metabolic syndrome, prediabetes\/diabetes and non-alcoholic fatty liver disease\u2014current evidence","volume":"27","author":"Muzurovi\u0107 EM","year":"2022","unstructured":"Muzurovi\u0107 EM, Vol\u010dan\u0161ek \u0160, Tom\u0161i\u0107 KZ, Jane\u017e A, Mikhailidis DP, Rizzo M, Mantzoros CS. Glucagon-like peptide-1 receptor agonists and dual glucose-dependent insulinotropic polypeptide\/glucagon-like peptide-1 receptor agonists in the treatment of obesity\/metabolic syndrome, prediabetes\/diabetes and non-alcoholic fatty liver disease\u2014current evidence. J Cardiovasc Pharmacol Ther. 2022, 27:14-6. 10.1177\/10742484221146371","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12061320","article-title":"New developments in pharmacological treatment of obesity and type 2 diabetes-beyond and within GLP-1 receptor agonists","volume":"12","author":"Sztanek F","year":"2024","unstructured":"Sztanek F, T\u00f3th LI, Pet\u0151 A, Herny\u00e1k M, Di\u00f3szegi \u00c1, Harangi M. New developments in pharmacological treatment of obesity and type 2 diabetes-beyond and within GLP-1 receptor agonists. Biomedicines. 2024, 12:32-4. 10.3390\/biomedicines12061320","journal-title":"Biomedicines"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103363","article-title":"The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions","volume":"86","author":"Moiz A","year":"2025","unstructured":"Moiz A, Filion KB, Tsoukas MA, Yu OH, Peters TM, Eisenberg MJ. The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions. EClinicalMedicine. 2025, 86:103363. 10.1016\/j.eclinm.2025.103363","journal-title":"EClinicalMedicine"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-016-9389-5","article-title":"Beyond acne: current aspects of sebaceous gland biology and function","volume":"17","author":"Zouboulis CC","year":"2016","unstructured":"Zouboulis CC, Picardo M, Ju Q, Kurokawa I, T\u00f6r\u0151csik D, B\u00edr\u00f3 T, Schneider MR. Beyond acne: current aspects of sebaceous gland biology and function. Rev Endocr Metab Disord. 2016, 17:319-34. 10.1007\/s11154-016-9389-5","journal-title":"Rev Endocr Metab Disord"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23063132","article-title":"Unraveling the role of sex hormones on keratinocyte functions in human inflammatory skin diseases","volume":"23","author":"Gratton R","year":"2022","unstructured":"Gratton R, Del Vecchio C, Zupin L, Crovella S. Unraveling the role of sex hormones on keratinocyte functions in human inflammatory skin diseases. Int J Mol Sci. 2022, 23:4-6. 10.3390\/ijms23063132","journal-title":"Int J Mol Sci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-016-9366","article-title":"Hidradenitis suppurativa\/Acne inversa: an endocrine skin disorder?","volume":"17","author":"Karagiannidis I","year":"2016","unstructured":"Karagiannidis I, Nikolakis G, Sabat R, Zouboulis CC. Hidradenitis suppurativa\/Acne inversa: an endocrine skin disorder?. Rev Endocr Metab Disord. 2016, 17:335-41. 10.1007\/s11154-016-9366","journal-title":"Rev Endocr Metab Disord"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1148209","article-title":"Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent","volume":"14","author":"Mehdi SF","year":"2023","unstructured":"Mehdi SF, Pusapati S, Anwar MS, et al.. Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent. Front Immunol. 2023, 14:1148209. 10.3389\/fimmu.2023.1148209","journal-title":"Front Immunol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s13671-025-00478-8","article-title":"Hidradenitis suppurativa flare management: a review of medical and procedural strategies","volume":"13","author":"Moon C","year":"2025","unstructured":"Moon C, Ghanshani R, Crew AB, Hughes M, Hsiao JL, Lee KH. Hidradenitis suppurativa flare management: a review of medical and procedural strategies. Curr Dermatol Rep. 2025, 13:27-9. 10.1007\/s13671-025-00478-8","journal-title":"Curr Dermatol Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1159\/000544023","article-title":"Dermatologic implications of glucagon-like peptide-1 receptor agonist medications","volume":"11","author":"Burke OM","year":"2025","unstructured":"Burke OM, Sa B, Cespedes DA, Tosti A. Dermatologic implications of glucagon-like peptide-1 receptor agonist medications. Skin Appendage Disord. 2025, 11:416-23. 10.1159\/000544023","journal-title":"Skin Appendage Disord"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Cao K. GLP-1 RAs and skin health: exploring dermatologic side effects and therapeutic interventions. (2025). Accessed: January 9, 2026: https:\/\/www.researchgate.net\/publication\/393046198_GLP-1_RAs_and_Skin_Health_Exploring_Dermatologic_Side_Effects_and_....","DOI":"10.20944\/preprints202506.1838.v1"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03257-w","article-title":"GLP-1 receptor agonists, DPP-4 inhibitors and the skin-diabetes meets dermatology: a brief narrative review","volume":"42","author":"Pantazopoulos D","year":"2025","unstructured":"Pantazopoulos D, Gouveri E, Papi M, Papazoglou D, Papanas N. GLP-1 receptor agonists, DPP-4 inhibitors and the skin-diabetes meets dermatology: a brief narrative review. Adv Ther. 2025, 42:3621-33. 10.1007\/s12325-025-03257-w","journal-title":"Adv Ther"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.93282","article-title":"Use of glucagon-like peptide-1 (GLP-1) agonists in modulating preexisting dermatologic disease: a systematic review","volume":"17","author":"Tassavor B","year":"2025","unstructured":"Tassavor B, Al Salem S. Use of glucagon-like peptide-1 (GLP-1) agonists in modulating preexisting dermatologic disease: a systematic review. Cureus. 2025, 17:e93282. 10.7759\/cureus.93282","journal-title":"Cureus"},{"key":"ref13","unstructured":"OZEMPIC (semaglutide) injection, for subcutaneous use. Initial U.S approval. (2017). Accessed. December 20, 2025: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209637lbl.pdf."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21615","article-title":"The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD\u2122): a clinical outcome measure for the severity of atopic dermatitis","volume":"187","author":"Simpson EL","year":"2022","unstructured":"Simpson EL, Bissonnette R, Paller AS, et al.. The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD\u2122): a clinical outcome measure for the severity of atopic dermatitis. Br J Dermatol. 2022, 187:531-8. 10.1111\/bjd.21615","journal-title":"Br J Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15748","article-title":"Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity","volume":"177","author":"Zouboulis CC","year":"2017","unstructured":"Zouboulis CC, Tzellos T, Kyrgidis A, et al.. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity. Br J Dermatol. 2017, 177:1401-9. 10.1111\/bjd.15748","journal-title":"Br J Dermatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13216292","article-title":"The therapeutic potential of GLP-1 receptor agonists in the management of hidradenitis suppurativa: a systematic review of anti-inflammatory and metabolic effects","volume":"13","author":"Krajewski PK","year":"2024","unstructured":"Krajewski PK, Z\u0142otowska A, Szepietowski JC. The therapeutic potential of GLP-1 receptor agonists in the management of hidradenitis suppurativa: a systematic review of anti-inflammatory and metabolic effects. J Clin Med. 2024, 13:32-4. 10.3390\/jcm13216292","journal-title":"J Clin Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/JW9.0000000000000143","article-title":"A meta-analysis of the incidence of acne vulgaris in patients treated with GLP-1 agonists","volume":"10","author":"Ogunremi OO","year":"2024","unstructured":"Ogunremi OO, Ismail SF, Dhami RK, Newton JS, Kindle SA, Kozmenko V. A meta-analysis of the incidence of acne vulgaris in patients treated with GLP-1 agonists. Int J Womens Dermatol. 2024, 10:e143. 10.1097\/JW9.0000000000000143","journal-title":"Int J Womens Dermatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/diseases13050127","article-title":"A closer look at the dermatological profile of GLP-1 agonists","volume":"13","author":"Persson C","year":"2025","unstructured":"Persson C, Eaton A, Mayrovitz HN. A closer look at the dermatological profile of GLP-1 agonists. Diseases. 2025, 13:26-8. 10.3390\/diseases13050127","journal-title":"Diseases"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.36849\/jdd.8926","article-title":"Glucagon-like peptide-1 receptor agonists reduce surgeries and hospitalizations in hidradenitis suppurativa: a multicenter TriNetX cohort study","volume":"24","author":"Gupta N","year":"2025","unstructured":"Gupta N, Zafar K, Patel P, et al.. Glucagon-like peptide-1 receptor agonists reduce surgeries and hospitalizations in hidradenitis suppurativa: a multicenter TriNetX cohort study. J Drugs Dermatol. 2025, 24:869-74. 10.36849\/jdd.8926","journal-title":"J Drugs Dermatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2023.11.007","article-title":"Liraglutide for the treatment of obesity among patients with hidradenitis suppurativa","volume":"162","author":"Nicolau J","year":"2024","unstructured":"Nicolau J, Nadal A, Sanch\u00eds P, Pujol A, Masmiquel L, Nadal C. Liraglutide for the treatment of obesity among patients with hidradenitis suppurativa. Med Clin (Barc). 2024, 162:118-22. 10.1016\/j.medcli.2023.11.007","journal-title":"Med Clin (Barc)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.22541\/au.175521972.20484170\/v1","article-title":"Dermatological adverse reactions and therapeutic potential of semaglutide, liraglutide and tirzepatide: analysis of UK pharmacovigilance data and literature review","volume":"4","author":"Fattahi A","year":"2025","unstructured":"Fattahi A, Salako K. Dermatological adverse reactions and therapeutic potential of semaglutide, liraglutide and tirzepatide: analysis of UK pharmacovigilance data and literature review. Authorea [PREPRINT]. 2025, 4:23-5. 10.22541\/au.175521972.20484170\/v1","journal-title":"Authorea [PREPRINT]"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/446986-the-impact-of-glucagon-like-peptide-1-glp-1-agonists-on-acne-hidradenitis-and-sebaceous-activity","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T09:06:08Z","timestamp":1768035968000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/446986-the-impact-of-glucagon-like-peptide-1-glp-1-agonists-on-acne-hidradenitis-and-sebaceous-activity"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,10]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.101212","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,10]]}}}